Contra-indicated in patients with active pathological bleeding.
- TRADE NAME: Eliquis (Bristol-Myers Squibb)
- INDICATIONS: Reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
- CLASS: Anticoagulant (antithrombotic), Direct factor Xa inhibitor
- HALF-LIFE: 5–12 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Darunavir, Phenytoin, Rifampin, St John's Wort, Tipranavir, Voriconazole
- See adverse reactions attributed to class:
DISCONTINUING ELIQUIS IN PATIENTS WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of apixaban in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 04/24/2025
